Thomas Chalopin

609 total citations
20 papers, 54 citations indexed

About

Thomas Chalopin is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Thomas Chalopin has authored 20 papers receiving a total of 54 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 9 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Thomas Chalopin's work include Multiple Myeloma Research and Treatments (10 papers), Protein Degradation and Inhibitors (4 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (4 papers). Thomas Chalopin is often cited by papers focused on Multiple Myeloma Research and Treatments (10 papers), Protein Degradation and Inhibitors (4 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (4 papers). Thomas Chalopin collaborates with scholars based in France, Belgium and United States. Thomas Chalopin's co-authors include Olivier Hérault, Emmanuel Gyan, Nicolas Vallet, Cécile Le Brun, Julien Lejeune, Lotfi Benboubker, Chantal Barin‐Le Guellec, Philippe Colombat, Marion Morel and Flavie Arbion and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Blood.

In The Last Decade

Thomas Chalopin

16 papers receiving 53 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Chalopin France	5	19	19	15	8	7	20	54
Marwan Shaheen Saudi Arabia	7	16 0.8×	48 2.5×	14 0.9×	5 0.6×	6 0.9×	17	74
Rebecca Schleicher Germany	2	45 2.4×	24 1.3×	9 0.6×	4 0.5×	6 0.9×	2	91
Serdar Nepesov Türkiye	6	12 0.6×	22 1.2×	7 0.5×	10 1.3×	21 3.0×	19	80
Catherine Sobieski United States	5	20 1.1×	62 3.3×	35 2.3×	10 1.3×	6 0.9×	8	137
Sachiko Ando Japan	5	12 0.6×	27 1.4×	24 1.6×	9 1.1×	8 1.1×	11	65
Florian Renosi France	6	15 0.8×	17 0.9×	10 0.7×	2 0.3×	20 2.9×	15	88
Alexander Shaffer United States	5	17 0.9×	15 0.8×	7 0.5×	5 0.6×	6 0.9×	8	65
Betsy Valles United States	5	10 0.5×	19 1.0×	23 1.5×	15 1.9×	4 0.6×	5	79
Heike Martin Germany	4	29 1.5×	11 0.6×	19 1.3×	2 0.3×	6 0.9×	5	68
Hanadi Rafii France	6	14 0.7×	43 2.3×	14 0.9×	5 0.6×	13 1.9×	15	78

Countries citing papers authored by Thomas Chalopin

Since Specialization

Citations

This map shows the geographic impact of Thomas Chalopin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Chalopin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Chalopin more than expected).

Fields of papers citing papers by Thomas Chalopin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Chalopin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Chalopin. The network helps show where Thomas Chalopin may publish in the future.

Co-authorship network of co-authors of Thomas Chalopin

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Chalopin. A scholar is included among the top collaborators of Thomas Chalopin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Chalopin. Thomas Chalopin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Talbot, Alexis, Cyrille Hulin, Aurore Perrot, et al.. (2025). Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort Study. Clinical Lymphoma Myeloma & Leukemia. 25(12). 863–872. 1 indexed citations

Perrot, Aurore, Cyrille Hulin, Jérôme Lambert, et al.. (2025). MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial.. Journal of Clinical Oncology. 43(16_suppl). 7500–7500. 1 indexed citations

Hulin, Cyrille, Bruno Royer, Margaret Macro, et al.. (2025). Real-World Utilization of Carfilzomib (Once or Twice Weekly) Initiated in Patients After a First Relapse Between 2017 and 2022 in France: An Analysis From a Large-Scale Epidemiology of Multiple MYeloma (EmmY) Cohort. Clinical Lymphoma Myeloma & Leukemia. 26(1). e1–e11.e4.

Hulin, Cyrille, Jérôme Lambert, Salomon Manier, et al.. (2024). Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).. Journal of Clinical Oncology. 42(16_suppl). 7501–7501. 1 indexed citations

Wyngaert, Zoé Van de, Murielle Roussel, Marguerite Vignon, et al.. (2024). Effect of Daratumumab on Renal Outcome in Newly Diagnosed Multiple Myeloma with Light Chain CAST Nephropathy. Blood. 144(Supplement 1). 1980–1980.

Matous, Jeffrey, Albert Oriol, Alfred L. Garfall, et al.. (2024). Higher Teclistamab Step-up Dosing in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from the Majestec-1 Trial. Blood. 144(Supplement 1). 4749–4749.

Touzeau, Cyrille, Xavier Leleu, Mourad Tiab, et al.. (2024). All-oral triplet iberdomide, ixazomib, and dexamethasone in elderly patients with multiple myeloma at first relapse: Results of the IFM phase 2 study I2D.. Journal of Clinical Oncology. 42(16_suppl). 7507–7507. 1 indexed citations

Chalopin, Thomas, Hélène Demarquette, Cécile Sonntag, et al.. (2024). Debulking Conventional Chemotherapy before Treatment By Anti-BCMA Bispecific Antibody in Extramedullary and/or High Tumor Burden Relapsed/Refractory Multiple Myeloma. Blood. 144(Supplement 1). 1986–1986.

Chari, Ajai, Lionel Karlin, Amrita Krishnan, et al.. (2024). Analysis of Repeat Step-up Dosing and Cytokine Release Syndrome Events Following Prolonged Dosing Intervals of Teclistamab in the Phase 1/2 Majestec-1 Study. Blood. 144(Supplement 1). 4734–4734. 1 indexed citations

10.

Chalopin, Thomas, Annabelle Bohrdt, Eugene Demler, et al.. (2023). Magnetically mediated hole pairing in fermionic ladders of ultracold atoms. Nature. 613(7944). 463–467. 2 indexed citations

11.

Roussel, Murielle, Bruno Royer, Stéphanie Harel, et al.. (2023). B01 VENETOCLAX TARGETED THERAPY in AL AMYLOIDOSIS PATIENTS: A RETROSPECTIVE ANALYSIS FROM THE FRENCH AMYLOIDOSIS NETWORK. HemaSphere. 7(S2). 4–4. 4 indexed citations

12.

Roussel, Murielle, Thomas Chalopin, Olivier Decaux, et al.. (2022). Venetoclax-Targeted Therapy in t(11;14) AL Amyloidosis Patients after Frontline Daratumumab and Cybord: A Retrospective Analysis from the French Amyloidosis Network. Blood. 140(Supplement 1). 10086–10087. 2 indexed citations

13.

Chalopin, Thomas, Nicolas Vallet, Marion Morel, et al.. (2021). Eosinophilic fasciitis (Shulman syndrome), a rare entity and diagnostic challenge, as a manifestation of severe chronic graft-versus-host disease: a case report. Journal of Medical Case Reports. 15(1). 135–135. 7 indexed citations

14.

Vallet, Nicolas, Martine Ropert, Thomas Chalopin, et al.. (2021). Megaloblastic anemia-related iron overload and erythroid regulators: a case report. Journal of Medical Case Reports. 15(1). 463–463. 1 indexed citations

15.

Chalopin, Thomas, et al.. (2020). Retrospective review of end-of-life care in the last month of life in older patients with multiple myeloma: what collaboration between haematologists and palliative care teams?. BMJ Supportive & Palliative Care. 14(e1). e380–e383. 5 indexed citations

16.

Vallet, Nicolas, Marjan Ertault, Thomas Chalopin, et al.. (2020). Hypercalcemia is associated with a poor prognosis in lymphoma a retrospective monocentric matched-control study and extensive review of published reported cases. Annals of Hematology. 99(2). 229–239. 8 indexed citations

17.

Brun, Cécile Le, Thomas Chalopin, Julien Le Marec, et al.. (2019). Severe infections due to Francisella tularensis ssp. holarctica in solid organ transplant recipient: report of two cases and review of literature. BMC Infectious Diseases. 19(1). 238–238. 10 indexed citations

18.

Chalopin, Thomas, Nicolas Vallet, Flavie Arbion, et al.. (2019). Characteristics, combinations, treatments, and survival of second primary hematological neoplasm: a retrospective single-center cohort of 49 patients (Hemo2study). Annals of Hematology. 98(10). 2367–2377. 1 indexed citations

19.

Chalopin, Thomas, Adrien Lemaignen, Antoine Guillon, et al.. (2018). Acute Tibial osteomyelitis caused by intraosseous access during initial resuscitation: a case report and literature review. BMC Infectious Diseases. 18(1). 665–665. 4 indexed citations

20.

Chalopin, Thomas, I. Barillot, Flavie Arbion, et al.. (2017). Primary solitary plasmacytoma of the liver – successful treatment with fractionated stereotactic radiotherapy (Cyberknife®): a case report. Journal of Medical Case Reports. 11(1). 193–193. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact